Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 6Terminated 2Recruiting 2Withdrawn 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia, Myelomonocytic, Chronic 8Primary Myelofibrosis 5Myeloproliferative Disorders 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4Hodgkin Disease 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Neuroblastoma 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Graft vs Host Disease 2Ganglioneuroblastoma 2Burkitt Lymphoma 2Thrombocythemia, Essential 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Non-Malignant Neoplasm 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Temozolomide 16Irinotecan 13Cyclophosphamide 11dinutuximab 9naxitamab 7Vincristine 7Carboplatin 6sargramostim 5Melphalan 5Granulocyte-Macrophage Colony-Stimulating Factor 5Etoposide 5fludarabine 4Topotecan 4Thiotepa 4Eflornithine 4Doxorubicin 4Cisplatin 4etoposide phosphate 3Zoledronic Acid 3Specimen Handling 3Isotretinoin 3Granulocyte Colony-Stimulating Factor 3saponin QA-21V1 2lutetium Lu 177 dotatate 2aldesleukin 2Vorinostat 2Stem Cell Transplantation 2Radiation 2Platinum 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neuroblastoma × Stem Cell Transplantation × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡